PMID- 37415638
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230718
IS  - 2405-6308 (Electronic)
IS  - 2405-6308 (Linking)
VI  - 42
DP  - 2023 Sep
TI  - Impact of hyperfractionated re-irradiation on quality of life in patients with 
      recurrent or second primary head and neck cancer, a prospective single 
      institutional study.
PG  - 100654
LID - 10.1016/j.ctro.2023.100654 [doi]
LID - 100654
AB  - PURPOSE: Describe the clinical outcome of hyperfractionated re-irradiation (HFRT) 
      in patients with recurrent or second primary (SP) head and neck cancer (HNC). 
      METHODS: This prospective observational study included HNC patients eligible for 
      HFRT. Inclusion criteria: age >/=18 years, recurrent or SP HNC, planned 
      re-irradiation and ability to respond to questionnaires. Patients received 1.5 Gy 
      twice daily, five days a week for three (palliative) or four (curative/local 
      control) weeks, total dose 45/60 Gy. Toxicity was scored with CTCAE v3 at 
      baseline, end of treatment, at three, six, 12 and 36 months follow-up. 
      Health-related quality of life (HRQoL) was measured with EORTC QLQ-C30 and EORTC 
      QLQ-H&N35, pre-treatment and eight times until 36 months. In the main outcome 
      (Global quality of life and H&N Pain), a change score of >/=10 was considered 
      clinically significant, and p-values < 0.05 (two-sided) statistically 
      significant. The Kaplan-Meier method was used for survival analyses. RESULTS: 
      Over four years from 2015, 58 patients were enrolled (37 recurrent and 21 SP). 
      All, but two patients completed treatment as planned. Toxicity (>/=grade 3) 
      increased from pre-treatment to end of treatment with improvement in the 
      follow-up period. The mean Global quality of life (QoL) and H&N Pain scores were 
      stable from pre-treatment to three months. Maintained/ improved Global QoL was 
      reported by 60% of patients at three months and 56% of patients at 12 months. For 
      patients with curative, local control and palliative intent, the median survival 
      (range) was 23 (2-53), 10 (1-66) and 14 (3-41) months respectively. Of those 
      alive, the proportion of disease-free patients at 12 and 36 months, were 58% and 
      48%, respectively. CONCLUSION: Most HNC patients reported maintained HRQoL at 
      three and 12 months after HFRT despite serious toxicity observed in many 
      patients. Long-term survival can be achieved in a limited proportion of the 
      patients.
CI  - (c) 2023 Oslo University Hospital.
FAU - Amdal, Cecilie Delphin
AU  - Amdal CD
AD  - Department of Oncology, Oslo University Hospital, Oslo, Norway.
AD  - Research Support Services, Oslo University Hospital, Oslo, Norway.
FAU - Moan, Jon Magne
AU  - Moan JM
AD  - Department of Oncology, Oslo University Hospital, Oslo, Norway.
FAU - Dale, Einar
AU  - Dale E
AD  - Department of Oncology, Oslo University Hospital, Oslo, Norway.
FAU - Falk, Ragnhild Sorum
AU  - Falk RS
AD  - Research Support Services, Oslo University Hospital, Oslo, Norway.
FAU - Johansen, Safora
AU  - Johansen S
AD  - Department of Oncology, Oslo University Hospital, Oslo, Norway.
AD  - Oslo Metropolitan University, Faculty of Health Sciences, Oslo, Norway.
FAU - Bjordal, Kristin
AU  - Bjordal K
AD  - Research Support Services, Oslo University Hospital, Oslo, Norway.
AD  - University of Oslo, Faculty of Medicine, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20230622
PL  - Ireland
TA  - Clin Transl Radiat Oncol
JT  - Clinical and translational radiation oncology
JID - 101713416
PMC - PMC10319815
OTO - NOTNLM
OT  - Head and neck cancer
OT  - Health-related quality of life
OT  - Patient-reported outcome measure
OT  - Radiotherapy
OT  - Recurrent disease
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/07/07 06:42
MHDA- 2023/07/07 06:43
PMCR- 2023/06/22
CRDT- 2023/07/07 03:55
PHST- 2023/03/15 00:00 [received]
PHST- 2023/05/19 00:00 [revised]
PHST- 2023/06/17 00:00 [accepted]
PHST- 2023/07/07 06:43 [medline]
PHST- 2023/07/07 06:42 [pubmed]
PHST- 2023/07/07 03:55 [entrez]
PHST- 2023/06/22 00:00 [pmc-release]
AID - S2405-6308(23)00079-4 [pii]
AID - 100654 [pii]
AID - 10.1016/j.ctro.2023.100654 [doi]
PST - epublish
SO  - Clin Transl Radiat Oncol. 2023 Jun 22;42:100654. doi: 10.1016/j.ctro.2023.100654. 
      eCollection 2023 Sep.